Specific association of MTHFD1 expressions with small cell lung cancer development and chemoradiotherapy outcome.

IF 1.7 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Saudi Medical Journal Pub Date : 2024-08-01 DOI:10.15537/smj.2024.45.8.20230990

Yujia Hao, Ruichun Lu, Ying Guo, Pengtao Bao

{"title":"Specific association of MTHFD1 expressions with small cell lung cancer development and chemoradiotherapy outcome.","authors":"Yujia Hao, Ruichun Lu, Ying Guo, Pengtao Bao","doi":"10.15537/smj.2024.45.8.20230990","DOIUrl":null,"url":null,"abstract":"Objectives: To identify biomarkers that can discriminated small cell lung cancer (SCLC) from non-SCLC (NSCLC), and explore their association with the prognosis of SCLC under chemoradiotherapy.Methods: The GSE40275 dataset was used to identify potential targets in SCLC. There were 196 patients of lung cancer (LC) in cohort 1 of this study. MTHFD1 levels in tissues were determined by immunohistochemistry assay in cohort 1. Lung cancer patients who were all underwent local chemoradiotherapy (CRT) were included in cohort 2, and the association of MTHFD1 levels with CRT treatment outcome were determined in cohort 2. Cell experiments were used to determine the function of MTHFD1 on the radio-sensitivity of SCLC and NSCLC cells.Results: The MTHFD1 levels in LC tissues were increased, and could discriminate SCLC from both lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD). Small cell lung cancer patients with MTHFD1 high phenotype had a poorer prognosis after CRT treatment, whereas no significant correlation was found between MTHFD1 levels and prognosis in LUSC and LUAD group. Cell experiments demonstrated that overexpression of MTHFD1 increases radio-resistance in both SCLC and NSCLC in vitro.Conclusion: MTHFD1 expressions might be a novel specifically prognostic biomarker for SCLC and the CRT treatment outcome.","PeriodicalId":21453,"journal":{"name":"Saudi Medical Journal","volume":"45 8","pages":"783-790"},"PeriodicalIF":1.7000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11288495/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Saudi Medical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15537/smj.2024.45.8.20230990","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To identify biomarkers that can discriminated small cell lung cancer (SCLC) from non-SCLC (NSCLC), and explore their association with the prognosis of SCLC under chemoradiotherapy.

Methods: The GSE40275 dataset was used to identify potential targets in SCLC. There were 196 patients of lung cancer (LC) in cohort 1 of this study. MTHFD1 levels in tissues were determined by immunohistochemistry assay in cohort 1. Lung cancer patients who were all underwent local chemoradiotherapy (CRT) were included in cohort 2, and the association of MTHFD1 levels with CRT treatment outcome were determined in cohort 2. Cell experiments were used to determine the function of MTHFD1 on the radio-sensitivity of SCLC and NSCLC cells.

Results: The MTHFD1 levels in LC tissues were increased, and could discriminate SCLC from both lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD). Small cell lung cancer patients with MTHFD1 high phenotype had a poorer prognosis after CRT treatment, whereas no significant correlation was found between MTHFD1 levels and prognosis in LUSC and LUAD group. Cell experiments demonstrated that overexpression of MTHFD1 increases radio-resistance in both SCLC and NSCLC in vitro.

Conclusion: MTHFD1 expressions might be a novel specifically prognostic biomarker for SCLC and the CRT treatment outcome.

查看原文本刊更多论文

MTHFD1的表达与小细胞肺癌的发展和化疗放疗结果的特异性关联

目的找出能区分小细胞肺癌（SCLC）和非小细胞肺癌（NSCLC）的生物标志物，并探讨它们与化疗放疗下SCLC预后的关系：方法：利用GSE40275数据集鉴定SCLC中的潜在靶点。该研究的队列 1 共有 196 例肺癌患者。队列 1 中组织中的 MTHFD1 水平是通过免疫组化检测确定的。队列 2 中的肺癌患者均接受了局部放化疗（CRT），并在队列 2 中测定了 MTHFD1 水平与 CRT 治疗结果的相关性。细胞实验用于确定MTHFD1对SCLC和NSCLC细胞放射敏感性的作用：LC组织中的MTHFD1水平升高，可将SCLC与肺鳞癌（LUSC）和肺腺癌（LUAD）区分开来。MTHFD1高表型的小细胞肺癌患者经CRT治疗后预后较差，而LUSC和LUAD组的MTHFD1水平与预后无明显相关性。细胞实验表明，MTHFD1在体外过表达会增加SCLC和NSCLC的放射抗性：结论：MTHFD1的表达可能是SCLC和CRT治疗结果的一种新型特异性预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Saudi Medical Journal 医学-医学：内科

CiteScore

2.30

自引率

6.20%

发文量

203

审稿时长

12 months

期刊介绍： The Saudi Medical Journal is a monthly peer-reviewed medical journal. It is an open access journal, with content released under a Creative Commons attribution-noncommercial license. The journal publishes original research articles, review articles, Systematic Reviews, Case Reports, Brief Communication, Brief Report, Clinical Note, Clinical Image, Editorials, Book Reviews, Correspondence, and Student Corner.